Dallas, TX -- (SBWIRE) -- 11/17/2010 -- SandlerResearch announce Colorectal Cancer - Germany Drug Forecasts and Treatment Analysis to 2020
Original Source : Colorectal Cancer Market
http://www.sandlerresearch.org/reports/36439-colorectal-cancer-germany-drug-forecasts-and-treatment-analysis.html
Buy Now : Market Research
http://www.sandlerresearch.org/reports/15763-major-depressive-disorder-mdd-drug-pipeline-analysis-and-mark.html
Browse complete Report at : http://www.sandlerresearch.org/reports/36439-colorectal-cancer-germany-drug-forecasts-and-treatment-analysis.html
GlobalData, the industry analysis specialist, has released its new report, “Colorectal Cancer - Germany Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the German colorectal cancer therapeutics market. The report provides comprehensive information on colorectal cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the German colorectal cancer therapeutics market. It analyses the treatment usage patterns in the German colorectal cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global colorectal cancer sector. It quantifies the unmet need in the German colorectal cancer therapeutics market, highlighting the opportunity for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The scope of the report includes:
An overview of colorectal cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
Annualized German colorectal cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data from 2001 to 2009, forecast for 11 years to 2020.
Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
Competitor assessment including drug launch analysis and drug sales forecasts.
Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, LCM activities and drug sales forecast.
Analysis of unmet need in the market and target product profile including opportunity for target product.
Technology trends analytic framework to assess strength of pipeline.
Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include EGFR inhibitors, VEGF inhibitors, monoclonal antibodies, angiogenesis inhibitors and others.
An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights and launch analysis.
Analysis of the current and future market competition in the German Colorectal Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Hoffmann-La Roche Ltd, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Debiopharm Group and Merck KGaA.
Analysis of licensing agreements during 2004-2010 in the colorectal cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
Direct quotes from key opinion leaders (KOL) or physicians in the colorectal cancer therapeutics market in Germany.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
Develop business strategies and perform superior market quantification analysis by
Understanding the trends shaping and driving the German colorectal cancer therapeutics market.
Understanding treatment preferences of physicians in disease state and across treatment flow.
Accessing market sizing, forecasts and quantified growth opportunities in the German colorectal cancer therapeutics market till 2020.
Quantifying patient population in Germany to better design product pricing & launch plans.
Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
Performing benchmarking analysis and growth opportunities against currently marketed products
Identifying market entry points based on safety, efficacy, and pricing parameters.
Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
Develop and design your in-licensing and out-licensing strategies by
Taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
Track drug sales in the German colorectal cancer therapeutics market from 2001 to 2020
Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
What’s the next big thing in the German Colorectal Cancer therapeutics market landscape? Identify, understand and capitalize.
Table Of Contents
1 Colorectal Cancer: Executive Summary 13
1.1 The Colorectal Cancer Therapeutics Market in Germany was Worth $540.5m in 2009, Driven by the Growth in the Patient Volume and Annual Cost of Colorectal Cancer Therapy 13
1.2 The Current Competition in the Colorectal Cancer Therapeutics Market is Weak as None of the Drugs Completely Addressed the Unmet Needs 14
1.3 The Colorectal Cancer Pipeline is Strong with Many Novel First-in-class Molecules in Late-stage Clinical Development 14
1.4 High Unmet Needs Exist in the Colorectal Cancer Therapeutics Market in terms of Efficacy and Safety 15
2 Disease Overview 17
2.1 Overview 17
2.2 Epidemiology 18
2.3 Etiology 18
2.4 Symptoms 19
2.4.1 Colon Cancer 19
2.4.2 Rectal Cancer 19
2.5 Diagnosis 20
2.5.1 FOBT 20
2.5.1.1 Sensitivity 20
2.5.2 Endoscopy 20
2.5.2.1 Sigmoidoscopy 20
2.5.2.2 Sensitivity 20
2.5.3 Optical Colonoscopy 20
2.5.3.1 Sensitivity 20
2.5.4 Virtual Colonoscopy 20
2.5.4.1 Sensitivity 20
2.5.5 Double Contrast Barium Enema (DCBE) 21
2.5.5.1 Sensitivity 21
2.6 Pathology 21
2.6.1 Grading 21
2.7 Treatment 22
2.7.1 Colon Cancer Treatment by Stage 22
2.7.2 Rectal Cancer Treatment by Stage 24
2.7.3 Chemotherapy Options 26
2.7.3.1 Adjuvant Treatment 26
2.7.3.2 First-line Treatment 27
2.7.3.3 Second-line Treatment 27
2.7.3.4 Third-line Treatment 27
2.8 Treatment Guidelines 27
3 Market Characterization 30
3.1 Germany 30
3.1.1 Market Size 30
3.1.1.1 Sales Value 30
3.1.1.2 Annual Cost of Therapy 31
3.1.1.3 Patient Volume 32
3.1.1.4 Treatment Usage Patterns 33
3.1.2 Drivers and Barriers 35
3.1.2.1 Drivers of the German Colorectal Cancer Market 35
3.1.2.2 Restraints of Germany colorectal Cancer Market 35
3.1.3 Impact on the Market 36
3.1.4 Forecasts 37
3.1.4.1 Sales Value 37
3.1.4.2 Annual Cost of Therapy 38
3.1.4.3 Patient Volume 39
3.1.4.4 Treatment Usage Patterns 40
3.1.4.5 Future Impact 42
3.1.5 Drug Sales 42
3.1.5.1 Overview 42
3.1.6 Pricing and Reimbursements 45
3.1.6.1 Pricing of Drugs in Germany 45
3.1.6.2 Reimbursement Policy in Germany 45
3.2 Key Takeaway 46
4 Competitor Assessment 47
4.1 Strategic Competitor Assessment 47
4.1.1 Overview 47
4.1.2 Benchmarking 47
4.1.2.1 Clinical Endpoints Benchmarking 47
4.1.2.2 Safety Profile 48
4.1.2.3 Annual Cost of Therapy 49
4.1.3 Current Competitor Assessment 49
4.2 Launch Analysis and Sales Forecasts 49
4.2.1 Market Share Analysis of Drugs 49
4.3 Product Profiles 51
4.3.1 Avastin (bevacizumab) 52
4.3.1.1 Overview 52
4.3.1.2 Efficacy 52
4.3.1.3 Safety 52
4.3.1.4 Clinical Study Details 53
4.3.1.5 Annual Cost of Therapy 53
4.3.1.6 Regulatory Approvals 53
4.3.1.7 Life Cycle Management Activities 54
4.3.1.8 Product Positioning 54
4.3.1.9 Sales Forecast 54
4.3.2 Erbitux (cetuximab) 55
4.3.2.1 Overview 55
4.3.2.2 Efficacy 55
4.3.2.3 Safety 56
4.3.2.4 Clinical Study Details 57
4.3.2.5 Annual Cost of Therapy 58
4.3.2.6 Regulatory Approvals 58
4.3.2.7 Life Cycle Management Activities 59
4.3.2.8 Product Positioning 59
4.3.2.9 Sales Forecast 60
4.3.3 Xeloda (capecitabine) 60
4.3.3.1 Overview 60
4.3.3.2 Efficacy 61
4.3.3.3 Safety 61
4.3.3.4 Clinical Study Details 62
4.3.3.5 Regulatory Approvals 63
4.3.3.6 Life Cyle Management Activities 63
4.3.3.7 Annual Cost of Therapy 63
4.3.3.8 Product Positioning 64
4.3.3.9 Sales Forecast 64
4.3.4 Vectibix (panitumumab) 64
4.3.4.1 Overview 64
4.3.4.2 Efficacy 65
4.3.4.3 Safety 65
4.3.4.4 Clinical Study Details 66
4.3.4.5 Regulatory Approvals 67
4.3.4.6 Life Cyle Management Activities 67
4.3.4.7 Annual Cost of Therapy 68
4.3.4.8 Product Positioning 68
4.3.4.9 Sales Forecast 68
4.3.5 Eloxatin (oxaliplatin) 68
4.3.5.1 Overview 68
4.3.5.2 Efficacy 69
4.3.5.3 Safety 70
4.3.5.4 Clinical Study Details 71
4.3.5.5 Regulatory Approvals 71
4.3.5.6 Life Cyle Management Activities 71
4.3.5.7 Annual Cost of Therapy 71
4.3.5.8 Product Positioning 72
4.3.5.9 Sales Forecast 72
4.3.6 Camptosar (irinotecan) 72
4.3.6.1 Overview 72
4.3.6.2 Efficacy 73
4.3.6.3 Safety 73
4.3.6.4 Clinical Study Details 73
4.3.6.5 Annual cost of Therapy 73
4.3.6.6 Regulatory approvals 73
4.3.6.7 Life Cyle Management Activities 74
4.3.6.8 Sales forecast 74
4.3.7 Fluorouracil (5-FU) 75
4.3.7.1 Overview 75
4.3.7.2 Efficacy 75
4.3.7.3 Safety 75
4.3.7.4 Annual Cost of Therapy 76
4.3.8 Leucovorin (folinic acid) 76
4.3.8.1 Overview 76
4.3.8.2 Efficacy 76
4.3.8.3 Safety 76
4.3.8.4 Annual Cost of Therapy 76
4.4 Key Takeaway 77
ABBREVIATIONS
Browse all : Pharmaceuticals Market
http://www.sandlerresearch.org/market-research/pharmaceuticals/
Browse all : GlobalData Market
http://www.sandlerresearch.org/publishers/globaldata/
Browse all : Newly Published Market Research
http://www.sandlerresearch.org/LatestReport.aspx
Related Reports :
Colorectal Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Q4 2010
http://www.sandlerresearch.org/Reports/36435-colorectal-cancer-global-drug-forecasts-and-treatment-analysis-.html
Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine
http://www.sandlerresearch.org/Reports/7701-pipeline-insight-colorectal-cancer-growing-trend-towards-perso.html
Disease and Therapy Review: Colorectal Cancer
http://www.sandlerresearch.org/Reports/25720-disease-and-therapy-review-colorectal-cancer.html
Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment
http://www.sandlerresearch.org/Reports/7152-stakeholder-insight-cancer-pain-physician-survey-highlights-in.html
About Sandler Research
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques, in order to generate better revenues for our clients, entailing positive and robust results.
We also provide 24/7 online and offline support to our customers
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.sandlerresearch.org
Blog: http://sandlerresearch.blogspot.com/